Our study revealed the unappreciated role of LGALS1 in chemoresistant AML patients and demonstrated the chemosensitizing efficacy of inhibiting LGALS1 in patient-derived primary AML cells, cell lines, and AML xenograft models. This evidence concerns the gene LGALS1 and acute myeloid leukemia.